Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer

References

• Smyth EC , Nilsson M , Grabsch HI , et al. Gastric cancer. Lancet . 2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-5 32861308
   PubMed Web of Science ®Google Scholar
• Venerito M , Ford AC , Rokkas T , et al. Review: prevention and management of gastric cancer. Helicobacter . 2020;25(Suppl S1):e12740. doi:10.1111/hel.12740 32918347
   PubMed Web of Science ®Google Scholar
• Wang FH , Shen L , Li J , et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun . 2019;39(1):10. doi:10.1186/s40880-019-0349-9
   PubMed Web of Science ®Google Scholar
• Rausei S , Lianos GD . Treatment of gastric cancer. Cancers . 2020;12(9):9. doi:10.3390/cancers12092627
   Web of Science ®Google Scholar
• Ilson DH . Advances in the treatment of gastric cancer. Curr Opin Gastroenterol . 2020;36(6):525–529. doi:10.1097/MOG.0000000000000679 32889823
   PubMed Web of Science ®Google Scholar
• Wang X-Z , Zeng Z-Y , Ye X , et al. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol . 2020;12(1):37–53. doi:10.4251/wjgo.v12.i1.37 31966912
   PubMed Web of Science ®Google Scholar
• Petrillo A , Smyth EC . Multimodality treatment for localized gastric cancer: state of the art and new insights. Curr Opin Oncol . 2020;32(4):347–355. doi:10.1097/CCO.0000000000000630 32541324
   PubMed Web of Science ®Google Scholar
• Zhao Q , Lian C , Huo Z , et al. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: a multicenter randomized clinical trial. Cancer Med . 2020;9(16):5731–5745. doi:10.1002/cam4.3224 32583567
   PubMed Web of Science ®Google Scholar
• Yan Y , Yang A , Lu L , et al. Impact of neoadjuvant therapy on minimally invasive surgical outcomes in advanced gastric cancer: an International Propensity Score-Matched Study. Ann Surg Oncol . 2020. doi:10.1245/s10434-020-09070-9
   Web of Science ®Google Scholar
• Kang Y-K , Cho H . Perioperative FLOT: new standard for gastric cancer? Lancet . 2019;393(10184):1914–1916. doi:10.1016/S0140-6736(18)33189-1 30982685
   PubMed Web of Science ®Google Scholar
• Al-Batran SE , Hofheinz RD , Pauligk C , et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the Phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol . 2016;17(12):1697–1708. doi:10.1016/S1470-2045(16)30531-9 27776843
   PubMed Web of Science ®Google Scholar
• Al-Batran SE , Homann N , Pauligk C , et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol . 2017;3(9):1237–1244. doi:10.1001/jamaoncol.2017.0515 28448662
   PubMed Web of Science ®Google Scholar
• Al-Batran SE , Homann N , Pauligk C , et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet . 2019;393(10184):1948–1957. doi:10.1016/S0140-6736(18)32557-1 30982686
   PubMed Web of Science ®Google Scholar
• Sah BK , Zhang B , Zhang H , et al. Neoadjuvant FLOT versus SOX Phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun . 2020;11(1):6093. doi:10.1038/s41467-020-19965-6 33257672
   PubMed Web of Science ®Google Scholar
• Scott LJ . Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs . 2018;78(7):747–758. doi:10.1007/s40265-018-0903-9 29663291
   PubMed Web of Science ®Google Scholar
• Nie S , Yang G , Lu H . Current molecular targeted agents for advanced gastric cancer. Onco Targets Ther . 2020;13:4075–4088. doi:10.2147/OTT.S246412 32494161
   PubMed Web of Science ®Google Scholar
• Zhou N , Zhang C , Liu D , et al. Apatinib in combination with S-1 as first-line treatment in patients with advanced metastatic gastric cancer: results from an open, exploratory, single-arm, phase II trial. Oncologist . 2020. doi:10.1002/onco.13613
   Web of Science ®Google Scholar
• Zheng Y , Yang X , Yan C , et al. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: a single-arm, open-label, phase II trial. Eur J Cancer . 2020;130:12–19. doi:10.1016/j.ejca.2020.02.013 32171104
   PubMed Web of Science ®Google Scholar
• Cheng H , Sun A , Guo Q , et al. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis. Drug Des Devel Ther . 2018;12:2173–2183. doi:10.2147/DDDT.S170678
   PubMed Web of Science ®Google Scholar
• Zhang J , Zang X , Liu Y , et al. Efficacy and perioperative safety of FLOT regimen in neoadjuvant chemotherapy for gastric adenocarcinoma. Chin J Gen Surg . 2020;11(35):847–851. doi:10.3760/cma.j.cn113855-20200607-00460
   Google Scholar
• Zhao Q , Guan L , Lv H , et al. Analysis of the efficacy prediction and prognostic factors for advanced gastric cancer treated with apatinib. China Oncol . 2018;3(28):203–209. doi:10.19401/j.cnki.1007-3639.2018.03.006
   Google Scholar
• Byrd DR , Brierley JD , Baker TP , et al. Current and future cancer staging after neoadjuvant treatment for solid tumors. CA Cancer J Clin . 2020. doi:10.3322/caac.21640
   PubMed Web of Science ®Google Scholar
• Cats A , Jansen EPM , van Grieken NCT , et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gast ric cancer (CRITICS): an international, open-label, randomised Phase 3 trial. Lancet Oncol . 2018;19(5):616–628. doi:10.1016/S1470-2045(18)30132-3 29650363
   PubMed Web of Science ®Google Scholar
• Kawazoe A , Fukuoka S , Nakamura Y , et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol . 2020;21(8):1057–1065. doi:10.1016/S1470-2045(20)30271-0 32589866
   PubMed Web of Science ®Google Scholar
• Fukuoka S , Hara H , Takahashi N , et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dos e-escalation, and dose-expansion phase ib trial (REGONIVO, EPOC1603). J Clin Oncol . 2020;38(18):2053–2061. doi:10.1200/JCO.19.03296 32343640
   PubMed Web of Science ®Google Scholar
• Wang K , Ren Y , Ma Z , et al. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis. Cancer Manag Res . 2019;11:3009–3020. doi:10.2147/CMAR.S200883 31114348
   PubMed Web of Science ®Google Scholar
• Schuhmacher C , Gretschel S , Lordick F , et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol . 2010;28(35):5210–5218. doi:10.1200/JCO.2009.26.6114 21060024
   PubMed Web of Science ®Google Scholar
• Rausei S , Bali CD , Lianos GD . Neoadjuvant chemotherapy for gastric cancer. Has the time to decelerate the enthusiasm passed us by? Semin Oncol . 2020;47(6):355–360. doi:10.1053/j.seminoncol.2020.07.003 32758372
   PubMed Web of Science ®Google Scholar
• Anter AH , Abdel-Latif RM . The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. Med Oncol . 2013;30(1):451. doi:10.1007/s12032-012-0451-1 23307258
   PubMed Web of Science ®Google Scholar
• Geng R , Song L , Li J , et al. The safety of apatinib for the treatment of gastric cancer. Expert Opin Drug Saf . 2018;17(11):1145–1150. doi:10.1080/14740338.2018.1535592 30324820
   PubMed Web of Science ®Google Scholar
• Tian Z , Wang X , Liu Z , et al. Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions. Cancer Manag Res . 2019;11:5293–5300. doi:10.2147/CMAR.S207150 31239779
   PubMed Web of Science ®Google Scholar